Menu Search
Equities

Viracta Therapeutics Inc

RYIG:DEU

Viracta Therapeutics Inc

Actions
  • Price (EUR)0.745
  • Today's Change0.03 / 4.20%
  • Shares traded0.00
  • 1 Year change-56.69%
  • Beta--
Data delayed at least 15 minutes, as of May 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.

  • Revenue in USD (TTM)0.00
  • Net income in USD-47.99m
  • Incorporated1998
  • Employees40.00
  • Location
    Viracta Therapeutics Inc2533 S COAST HWY 101, SUITE 210CARDIFF BY THE SEA 92007United StatesUSA
  • Phone+1 (858) 400-8470
  • Fax+1 (650) 266-3501
  • Websitehttps://www.viracta.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.